Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $196.2 million.

  • Pharming's Non-Current Assets rose 3688.41% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year increase of 3688.41%. This contributed to the annual value of $121.5 million for FY2024, which is 1704.09% down from last year.
  • Per Pharming's latest filing, its Non-Current Assets stood at $196.2 million for Q3 2025, which was up 3688.41% from $200.5 million recorded in Q2 2025.
  • Pharming's Non-Current Assets' 5-year high stood at $200.5 million during Q2 2025, with a 5-year trough of $130275.0 in Q3 2022.
  • Its 5-year average for Non-Current Assets is $130.9 million, with a median of $145.3 million in 2024.
  • In the last 5 years, Pharming's Non-Current Assets crashed by 9991.79% in 2022 and then skyrocketed by 11099575.9% in 2023.
  • Over the past 5 years, Pharming's Non-Current Assets (Quarter) stood at $149250.5 in 2021, then soared by 99261.15% to $148.3 million in 2022, then fell by 1.2% to $146.5 million in 2023, then decreased by 17.04% to $121.5 million in 2024, then skyrocketed by 61.41% to $196.2 million in 2025.
  • Its Non-Current Assets was $196.2 million in Q3 2025, compared to $200.5 million in Q2 2025 and $189.1 million in Q1 2025.